CN106266968A - 茵陈清肝利胆颗粒及其制备方法和应用 - Google Patents
茵陈清肝利胆颗粒及其制备方法和应用 Download PDFInfo
- Publication number
- CN106266968A CN106266968A CN201610795367.6A CN201610795367A CN106266968A CN 106266968 A CN106266968 A CN 106266968A CN 201610795367 A CN201610795367 A CN 201610795367A CN 106266968 A CN106266968 A CN 106266968A
- Authority
- CN
- China
- Prior art keywords
- parts
- artemisiae scopariae
- herba artemisiae
- herba
- heat removing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 56
- 239000008187 granular material Substances 0.000 title claims abstract description 53
- 239000000731 choleretic agent Substances 0.000 title claims abstract description 42
- 230000001989 choleretic effect Effects 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 51
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 241000237636 Pheretima Species 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims description 33
- 239000013543 active substance Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- -1 filter Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 2
- 230000002566 clonic effect Effects 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 14
- 230000001737 promoting effect Effects 0.000 abstract description 11
- 208000006454 hepatitis Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 231100000614 poison Toxicity 0.000 abstract description 7
- 239000003440 toxic substance Substances 0.000 abstract description 6
- 210000000232 gallbladder Anatomy 0.000 abstract description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 210000000952 spleen Anatomy 0.000 abstract description 3
- 230000002175 menstrual effect Effects 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 13
- 230000003908 liver function Effects 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 7
- 231100000283 hepatitis Toxicity 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010041660 Splenomegaly Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 241001251949 Xanthium sibiricum Species 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000010231 banlangen Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 206010041519 Spider naevus Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000024557 hepatobiliary disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- HVHKMUMXERBUAN-IFADSCNNSA-N mesobilirubin IXalpha Chemical compound N1C(=O)C(CC)=C(C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C)C(=O)N\3)CC)N2)CCC(O)=O)N1 HVHKMUMXERBUAN-IFADSCNNSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域,具体涉及一种茵陈清肝利胆颗粒及其制备方法和应用。所述茵陈清肝利胆颗粒,由如下重量份配比的原料药制成:茵陈15‑25份、龙胆15‑25份、虎杖10‑20份、龟甲25‑35份、地龙10‑20份、莪术10‑20份、柴胡25‑35份、蒲公英10‑20份、白花蛇舌草15‑25份、甘草5‑15份。诸药合用,共奏清肝利胆、清热解毒、和肝理脾、通经化瘀、软坚散结、滋阴清热的功效。可用于慢性肝炎引起的黄疸。
Description
技术领域
本发明属于医药技术领域,具体涉及一种茵陈清肝利胆颗粒及其制备方法和应用。
背景技术
黄疸型肝炎由于各种原因(甲、乙、丙肝等病毒、饮酒、药物等)作用于肝脏使肝细胞变性、破坏、坏死、肝脏细胞及纤维组织重构,导致胆小管被阻塞从而引起血中胆红素上升、肌肤黏膜黄染、尿黄如茶、肝区疼痛等症状的疾病。黄疸是临床常见病证之一,可见于西医多种肝胆疾患,尤以乙型肝炎多见。黄疸为现代医学的一个症状,多与肝胆等疾患有关,它的消退标志着疾病的好转。顽固性黄疸与肝细胞胆汁分泌器排泄障碍、肝内各级小胆管扭曲、闭塞、数目减少及胆汁粘稠、在毛细血管内运动速度减慢等诸多因素有关。本病西医尚无特效疗法,临床实践多采用大剂量维生素C静脉滴注,同时给予能量合剂及门冬氨酸钾镁、维生素K1、维生素B族等,以改善肝脏代谢,促进毒素排泄,从而达到治疗目的。中医多采用清热利湿、疏肝利胆、活血化瘀、温阳利湿等法而奏效。但临床常见一些顽固性黄疸用此法则效果较差。
专利CN1814211A公开了一种治疗急性黄疸型肝炎的中草药汤剂及制备方法,涉及治疗急性黄疸型肝炎的中草药配方。其主要成分为射干、仙鹤草、金钱草、白茅根、栀子根、板蓝根、大蓟、黄柏、女贞子、柴胡、龙胆草、棉茵陈、垂盆草、秦艽、虎杖、蒲公英、广玉金、茯苓、厚朴、陈皮、大青叶、凹叶景天、泽泻、鸡内金、苍术、白术、连翘、丹参、白矾、甘草。该发明把具有清热、解毒、利水功效的中草药,通过辨证配伍,起到除湿退黄的作用,从而达到治愈急性黄疸型肝炎的目的。本汤剂特点:制备容易、服用方便、治愈率较高。该专利对于急性黄疸型肝炎有效,对于慢性肝炎及其引起的黄疸,疗效不够理想。
专利CN103990081A公开了一种中药组合物在制备治疗婴幼儿黄疸药物中的用途。该发明所提供的一种中药组合物,其包括如下组分:板蓝根,茵陈,白茅根,金钱草,栀子,猪苓,丹参,蒲公英,车前草,连翘,柴胡,郁金,虎杖,龙胆草,夏枯草,甘草。该中药组合物在治疗或预防婴幼儿黄疸方面均具有很好的效果,且药物副作用低,具有显著的临床推广价值。但是,该中药组合物对于慢性迁延行肝炎及其引起的黄疸,疗效不够理想。
发明内容
为了解决上述的技术问题,本发明提供了一种茵陈清肝利胆颗粒及其制备方法。
一种茵陈清肝利胆颗粒,由如下重量份配比的原料药制成:
茵陈15-25份、龙胆15-25份、虎杖10-20份、龟甲25-35份、地龙10-20份、莪术10-20份、柴胡25-35份、蒲公英10-20份、白花蛇舌草15-25份、甘草5-15份。
优选的,上述的茵陈清肝利胆颗粒,由如下重量份配比的原料药制成:
茵陈18-22份、龙胆18-22份、虎杖13-17份、龟甲28-32份、地龙13-17份、莪术13-17份、柴胡28-32份、蒲公英13-17份、白花蛇舌草18-22份、甘草8-10份。
更优选的,上述的茵陈清肝利胆颗粒,由如下重量份配比的原料药制成:
茵陈20份、龙胆20份、虎杖15份、龟甲30份、地龙15份、莪术15份、柴胡30份、蒲公英15份、白花蛇舌草20份、甘草10份。
本发明的以上组成中,各味中药的重量是以生药计算的,如果以克为单位,如制成制剂,则因制剂的大小不同可制成100-1000剂。所述100-1000剂是指单位剂量的制剂形式,如片剂100-1000片,胶囊剂100-1000粒,颗粒剂100-1000g,口服液100-1000ml,膏剂100-1000g,丸剂100-1000丸等。
以上组成是按重量作为配比的,在生产时可按照相应比例增大或减少,如大规模生产可以以kg为单位,或以t(吨)为单位;小规模制剂也可以以g为单位。重量可以增大或者减小,但各组成之间的生药材重量配比的比例不变。
以上重量配比的比例是经过科学筛选得到的,对于特殊病人,如重症或轻症,肥胖或瘦小的病人,可以相应调整组成的量的配比,增加或减少不超过100%,药效基本不变。
本发明的茵陈清肝利胆颗粒,可单独或根据需要可以加入一些药物可接受的辅料,可以采用制剂学常规技术制备该药物制剂。在制成药物制剂时可以制成任何可药用的口服剂型,这些剂型选自:颗粒剂、片剂、胶囊剂、口服液、口含剂、丸剂、散剂,优选为颗粒剂。
上述的茵陈清肝利胆颗粒的制备方法,包含如下步骤:
(1)柴胡、龟甲、甘草粉碎成细粉,过筛,得药粉A;
(2)其余茵陈等七味药加水煎煮三次,加水量依次为药物重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并水煎液,滤过,滤液60℃浓缩至相对密度为1.20-1.30的稠膏,与药粉A混合,即得本发明茵陈清肝利胆颗粒的活性物质;
(3)该活性物质单独或与药物可接受的辅料混合,按照制剂学常规方法制得。
所述的药物可接受的辅料选自:淀粉、硬脂酸镁、甘露醇、山梨醇、山梨酸或钾盐、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素A、维生素C、维生素E、维生素D、氮酮、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、右旋糖苷、甘氨酸、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、丙二醇、乙醇、吐温60-80、司班-80、蜂蜡、羊毛脂、液体石蜡、十六醇、没食子酸酯类、三乙醇胺、碱性氨基酸、尿素、尿囊素、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙等。
上述的茵陈清肝利胆颗粒在制备治疗黄疸型肝炎药物中的应用。
本发明的茵陈清肝利胆颗粒的用法用量:用法与用量:开水冲服。一次1袋,一日2-3次:或遵医嘱。
中医认为,引起肝炎的原因为一种性质属于湿热的毒邪。湿热毒邪首先影响肝胆脾胃之间的正常生理关系。在此过程中的主要症状表现为黄疸、胁痛、食欲不振等。此时的基本治疗是清热解毒利湿、调和肝胆脾胃。如果继续发展,病情将由浅入深,进而出现面色晦暗,肝掌,舌质暗红,蜘蛛痣等气滞血瘀的症状。要采用舒肝理气、活血化瘀的治疗方法,后期可见腰膝酸软,疲乏无力,消瘦等气血不足,肝脾肾虚损的症状,采用补益气血、滋补肝肾等方法进行治疗。上述黄疸、胁痛、淤积和虚损四种代表症状,分别采用清热解毒、调和肝胆脾胃、活血化瘀和滋补肝肾的治疗,就是中医治疗肝炎的四种基本治法。
针对于肝炎不同阶段的衍化,设计了本发明的处方。本发明的茵陈清肝利胆颗粒的处方中,以茵陈清热利湿、疏达肝气为君药以退黄,臣以龙胆草清肝胆实火、泻下焦痰热,虎杖利湿退黄、活血化瘀、解毒止痛为佐药,柴胡疏肝理气,龟甲滋阴养血、软坚散结,蒲公英、地龙、白花蛇舌草、莪术以活血化瘀行气解毒为使药,甘草清热解毒,诸药合用,共奏清肝利胆、清热解毒、和肝理脾、通经化瘀、软坚散结、滋阴清热的功效。用于温热内蕴所致的黄疸、胁痛、食少、乏力、小便黄等症。该处方根据肝炎的疾病衍化特点而设计,其治疗理念和原则涉及到了肝炎的不同阶段,故对于各个阶段的肝炎引起的黄疸尤其是慢性肝炎引起的黄疸,降黄和改善肝功能效果更好。
具体实施方式
下面结合具体实施例对本发明作更进一步的说明,以便本领域的技术人员更了解本发明,但并不因此限制本发明。
实施例1
一种茵陈清肝利胆颗粒,由如下重量配比的原料药制成:
茵陈200g、龙胆200g、虎杖150g、龟甲300g、地龙150g、莪术150g、柴胡300g、蒲公英150g、白花蛇舌草200g、甘草100g。
该茵陈清肝利胆颗粒的制备方法:
(1)柴胡、龟甲、甘草粉碎成细粉,过筛,得药粉A;
(2)其余茵陈等七味药加水煎煮三次,加水量依次为药物重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并水煎液,滤过,滤液60℃浓缩至相对密度为1.20-1.30的稠膏,与药粉A混合,即得本发明茵陈清肝利胆颗粒的活性物质;
(3)该活性物质加入糊精,用75%乙醇制成颗粒,干燥,制成1000g,分装,即得。共分装成100袋,每袋10g。
实施例2
一种茵陈清肝利胆颗粒,由如下重量配比的原料药制成:
茵陈180g、龙胆220g、虎杖130g、龟甲320g、地龙130g、莪术170g、柴胡280g、蒲公英170g、白花蛇舌草180g、甘草100g。
该茵陈清肝利胆颗粒的制备方法:
(1)柴胡、龟甲、甘草粉碎成细粉,过筛,得药粉A;
(2)其余茵陈等七味药加水煎煮三次,加水量依次为药物重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并水煎液,滤过,滤液60℃浓缩至相对密度为1.20-1.30的稠膏,与药粉A混合,即得本发明茵陈清肝利胆颗粒的活性物质;
(3)该活性物质加入淀粉,用70%乙醇制成颗粒,干燥,制成1000g,分装,即得。共分装成100袋,每袋10g。
实施例3
一种茵陈清肝利胆颗粒,由如下重量配比的原料药制成:
茵陈220g、龙胆180g、虎杖170g、龟甲280g、地龙170g、莪术130g、柴胡320g、蒲公英130g、白花蛇舌草220g、甘草80g。
该茵陈清肝利胆颗粒的制备方法:
(1)柴胡、龟甲、甘草粉碎成细粉,过筛,得药粉A;
(2)其余茵陈等七味药加水煎煮三次,加水量依次为药物重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并水煎液,滤过,滤液60℃浓缩至相对密度为1.20-1.30的稠膏,与药粉A混合,即得本发明茵陈清肝利胆颗粒的活性物质;
(3)该活性物质加入淀粉,用70%乙醇制成颗粒,干燥,制成1000g,分装,即得。共分装成100袋,每袋10g。
实施例4
一种茵陈清肝利胆颗粒,由如下重量配比的原料药制成:
茵陈150g、龙胆250g、虎杖100g、龟甲350g、地龙100g、莪术200g、柴胡250g、蒲公英200g、白花蛇舌草150g、甘草150g。
该茵陈清肝利胆颗粒的制备方法:
(1)柴胡、龟甲、甘草粉碎成细粉,过筛,得药粉A;
(2)其余茵陈等七味药加水煎煮三次,加水量依次为药物重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并水煎液,滤过,滤液60℃浓缩至相对密度为1.20-1.30的稠膏,与药粉A混合,即得本发明茵陈清肝利胆颗粒的活性物质;
(3)该活性物质加入糊精,用80%乙醇制成颗粒,干燥,制成1000g,分装,即得。共分装成100袋,每袋10g。
实施例5
一种茵陈清肝利胆颗粒,由如下重量配比的原料药制成:
茵陈250g、龙胆150g、虎杖200g、龟甲250g、地龙200g、莪术100g、柴胡350g、蒲公英100g、白花蛇舌草250g、甘草50g。
该茵陈清肝利胆颗粒的制备方法:
(1)柴胡、龟甲、甘草粉碎成细粉,过筛,得药粉A;
(2)其余茵陈等七味药加水煎煮三次,加水量依次为药物重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并水煎液,滤过,滤液60℃浓缩至相对密度为1.20-1.30的稠膏,与药粉A混合,即得本发明茵陈清肝利胆颗粒的活性物质;
(3)该活性物质加入蔗糖,用70%乙醇制成颗粒,干燥,制成1000g,分装,即得。共分装成100袋,每袋10g。
对比例1
一种茵陈清肝利胆颗粒,由如下重量配比的原料药制成:
茵陈200g、龙胆200g、虎杖150g、莪术150g、柴胡300g、蒲公英150g、白花蛇舌草200g、甘草100g。
该茵陈清肝利胆颗粒的制备方法:
(1)柴胡、甘草粉碎成细粉,过筛,得药粉A;
(2)其余茵陈等六味药加水煎煮三次,加水量依次为药物重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并水煎液,滤过,滤液60℃浓缩至相对密度为1.20-1.30的稠膏,与药粉A混合,即得活性物质;
(4)该活性物质加入糊精,用75%乙醇制成颗粒,干燥,制成1000g,分装,即得。共分装成100袋,每袋10g。
对实施例1制备的茵陈清肝利胆颗粒进行了临床试验,详情如下:
1一般资料
共治疗乙型慢性黄疸型肝炎病人154例,其中男99例,女55例,年龄最小,12岁,最大71岁,平均38.2±10.3岁;病程最短半年,最长12年,平均3.2±1.5年。临床诊断参照1995年修订的/病毒性肝炎防治方案(试行)进行。随机分为治疗组和对照组,每组78例。分组后,两组在性别、年龄、病程、症状、体征、病情及各项肝功能指标检测等各方面具有可比性(P>0.05)。
2观察方法
治疗组口服本发明实施例1制备的茵陈清肝利胆颗粒,水冲服。一次1袋,一日3次。
对照组口服本发明对比例1制备的颗粒剂,水冲服。一次1袋,一日3次。
两组病人应酌情配合应用肌苷、能量合剂、维生素、氨基酸等保肝药,但不加用其它有退黄作用的中西药物。治疗后于第4周、第8周分别观察两组患者的肝功能及临床症状、体征等项目。
3疗效判定标准
主要观察退黄作用。胆红素及肝功能其它项以治疗后t检验进行比较;临床症状以服药后消失或基本消失者为有效;脾肿大以回缩甚至恢复正常者为有效;复常例数比较采用X2检验。
4结果
对胆红素的影响:由表1可知,治疗前两组肝功能各项指标比较无显著性差异(P>0.05)。从退黄方面看,治疗组与对照组相比,在降低T-Bil指标上,两组有显著性差异(P<0.05),在降低D-Bil指标方面,两组有极显著性差异(P<0.01)。在黄疸降低的同时,ALT、AKP等肝功指标也有所降低,但治疗组降低更加明显(P<0.05)。从两组肝功能复常情况看,治疗组在T-Bil、D-Bil、ALT、AKP方面明显优于对照组(P<0.05)。
对症状体征的影响由表2可知,随着肝功能各项指标的改善,两组患者的临床症状和体征也有明显好转,从两组患者的有效率比较可知治疗组的改善更加显著,尤其是胁痛、腹胀和脾肿大的改善与对照组相比有显著性差异(P<0.05)。
可见在处方中增加了动物药龟甲和地龙,血肉有情之品药性较强,可以显著增强降黄作用和改善部分肝功能。改善胁痛、腹胀和脾肿大的症状。
表1 胆红素及其它肝功能指标疗效比较(X±s)
注:与对照组比较,*P<0.05,**P<0.01;治疗后两组肝功能各项指标复常例数比,#P<0.05。
表2 两组患者症状、体征有效率比较
组别 | 胁痛(例)(%) | 腹胀(例)(%) | 乏力(例)(%) | 纳差(例)(%) | 脾肿大(例)(%) |
治疗组 | 74/75(98.67)* | 70/73(95.89)* | 65/68(94.15) | 63/69(84.06) | 33/58(56.89)* |
对照组 | 52/76(68.42) | 49/75(65.33) | 55/69(79.7) | 45/68(66.18) | 22/56(35.71) |
注:与对照组比较,P<0.05。
Claims (7)
1.一种茵陈清肝利胆颗粒,由如下重量份配比的原料药制成:
茵陈15-25份、龙胆15-25份、虎杖10-20份、龟甲25-35份、地龙10-20份、莪术10-20份、柴胡25-35份、蒲公英10-20份、白花蛇舌草15-25份、甘草5-15份。
2.根据权利要求1所述的茵陈清肝利胆颗粒,其特征在于,由如下重量份配比的原料药制成:茵陈18-22份、龙胆18-22份、虎杖13-17份、龟甲28-32份、地龙13-17份、莪术13-17份、柴胡28-32份、蒲公英13-17份、白花蛇舌草18-22份、甘草8-10份。
3.根据权利要求2所述的茵陈清肝利胆颗粒,其特征在于,由如下重量份配比的原料药制成:茵陈20份、龙胆20份、虎杖15份、龟甲30份、地龙15份、莪术15份、柴胡30份、蒲公英15份、白花蛇舌草20份、甘草10份。
4.根据权利要求1或2或3所述的茵陈清肝利胆颗粒,其特征在于,其剂型形式为口服制剂。
5.根据权利要求4所述的茵陈清肝利胆颗粒,其特征在于,其剂型形式为颗粒剂。
6.权利要求1或2或3所述的茵陈清肝利胆颗粒的制备方法,包含如下步骤:
(1)柴胡、龟甲、甘草粉碎成细粉,过筛,得药粉A;
(2)其余茵陈等七味药加水煎煮三次,加水量依次为药物重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并水煎液,滤过,滤液60℃浓缩至相对密度为1.20-1.30的稠膏,与药粉A混合,即得本发明茵陈清肝利胆颗粒的活性物质;
(3)该活性物质单独或与药物可接受的辅料混合,按照制剂学常规方法制得。
7.权利要求1或2或3所述的茵陈清肝利胆颗粒在制备治疗慢性黄疸型肝炎药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610795367.6A CN106266968A (zh) | 2016-08-31 | 2016-08-31 | 茵陈清肝利胆颗粒及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610795367.6A CN106266968A (zh) | 2016-08-31 | 2016-08-31 | 茵陈清肝利胆颗粒及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106266968A true CN106266968A (zh) | 2017-01-04 |
Family
ID=57673913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610795367.6A Pending CN106266968A (zh) | 2016-08-31 | 2016-08-31 | 茵陈清肝利胆颗粒及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106266968A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110755490A (zh) * | 2019-11-07 | 2020-02-07 | 陇荣 | 一种治疗慢性肝炎的药物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1365822A (zh) * | 2001-10-07 | 2002-08-28 | 夏吾多杰 | 一种舒肝利胆胶囊及其制备方法 |
CN103191361A (zh) * | 2013-04-11 | 2013-07-10 | 上海浦东高星生物技术研究所 | 利胆解郁颗粒 |
-
2016
- 2016-08-31 CN CN201610795367.6A patent/CN106266968A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1365822A (zh) * | 2001-10-07 | 2002-08-28 | 夏吾多杰 | 一种舒肝利胆胶囊及其制备方法 |
CN103191361A (zh) * | 2013-04-11 | 2013-07-10 | 上海浦东高星生物技术研究所 | 利胆解郁颗粒 |
Non-Patent Citations (1)
Title |
---|
戴凯超: "柴鳖棱莪茵胆汤治疗肝炎168例", 《现代医药卫生》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110755490A (zh) * | 2019-11-07 | 2020-02-07 | 陇荣 | 一种治疗慢性肝炎的药物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100518807C (zh) | 一种治疗肝硬化腹水的药物 | |
CN106390013B (zh) | 一种抑制结直肠癌肝转移的复方中药组合物其制备方法与应用 | |
CN102210844B (zh) | 一种治疗慢性肝炎的中药组合物及其制备方法 | |
CN102716383B (zh) | 一种治疗克罗恩病的中药组合物 | |
CN103463417B (zh) | 一种治疗肠易激综合征的中药 | |
CN102526345B (zh) | 一种治疗高血压的中药组合物 | |
CN104491695A (zh) | 一种治疗黄褐斑的药物组合物 | |
CN104116971B (zh) | 一种治疗肝病瘙痒的中药组合物及其制备方法 | |
CN106310040A (zh) | 一种治疗急性痛风性关节炎的中药组合物及其制备方法和应用 | |
CN106266968A (zh) | 茵陈清肝利胆颗粒及其制备方法和应用 | |
CN104436048A (zh) | 一种中药制剂在制备治疗气滞血瘀型黄褐斑药物中的用途 | |
CN103041233A (zh) | 一种治疗小儿腹泻的药物组合物及其制备方法 | |
CN100500189C (zh) | 一种治疗溃疡性结肠炎的药物及其制备方法 | |
CN102626506B (zh) | 一种用于治疗腹腔积液的中药 | |
CN111743990B (zh) | 一种基于肝络病理论治疗婴儿肝内胆汁淤积性肝病的中药 | |
CN102631618A (zh) | 一种治疗糖尿病的中药 | |
CN103520419B (zh) | 一种治疗梅核气的药物及其制备方法 | |
CN102824482A (zh) | 一种治疗黄疸型肝炎的中药组合物 | |
CN102764325B (zh) | 祛湿除痛中药组合物 | |
CN106581468A (zh) | 一种能够治疗胃溃疡的中药制备方法 | |
CN102784376B (zh) | 一种治疗纳呆型急性肾小球肾炎的中药制备方法 | |
CN106266967A (zh) | 丹七软肝胶囊及其制备方法和应用 | |
CN106138421A (zh) | 治疗肠道炎症的中药组合物及其制备方法及应用 | |
CN101167915B (zh) | 治疗慢性浅表性胃炎的中药组合物及其制备方法 | |
CN101983712A (zh) | 冠心病的新型治疗药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Tang Jie Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
RJ01 | Rejection of invention patent application after publication |